UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~Washington~~WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

~~Date~~February ~~of Report (Date of earliest event reported): October 23~~20, ~~2007~~2020

~~AVVAA~~Date of Report ~~WORLD~~(Date ~~HEALTH~~of ~~CARE~~earliest ~~PRODUCTS,~~event ~~INC.~~reported)

AVVAA WORLD HEALTH CARE PRODUCTS, INC. (~~EXACT NAME~~Exact OFname ~~REGISTRANT~~of ASregistrant ~~SPECIFIED~~as INspecified ~~CHARTER~~in its charter)

Nevada	~~000-31611~~	88000-~~395714~~31611		88-395714
(State or other jurisdiction of incorporation or organization)	~~(Commission File Number)~~	(~~IRS~~Commission ~~Employee~~File ~~Identification No.~~Number)		(IRS Employer Identification No.)

Box 459, 1710 Shuswap Ave Lumby, BC, Canada V0E 2G0	V0E 2G0
Box 459, 1710 Shuswap Ave, Lumby A1		V0E 2G0
(Address of principal executive offices)	~~(Zip Code)~~	(Zip Code)

~~Registrant’s telephone number, including area code: (250) 547~~407-~~2048~~284-5470

~~Check~~(Registrant's ~~the appropriate~~telephone ~~box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below~~number):

~~[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)~~__________________________________________

[(Former name ~~] Soliciting~~or ~~material~~former ~~pursuant~~address, toif ~~Rule~~changed ~~14a-12~~since ~~under~~last ~~the Exchange Act (17 CFR 240.14a-12~~report)

[Check the appropriate box below ~~] Pre~~if the Form 8-~~commencement~~K ~~communications~~filing ~~pursuant~~is intended to ~~Rule~~simultaneously ~~14d-2(b)~~satisfy ~~under~~the filing obligation of the ~~Exchange Act (17~~registrant ~~CFR~~under ~~240.14d-2(b))~~any of the following provisions:

~~[ ]~~ ◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~ITEM~~Indicate by ~~4.02 Non-Reliance~~check onmark ~~Previously~~whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 ~~Issued Financial~~of ~~Statements~~this chapter) or aRule ~~Related~~12b-2 ~~Audit~~of ~~Report~~the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

~~On October~~Emerging ~~23, our Chief Executive Officer and sole director, John S. Farley~~growth ~~determined~~company that our financial statements for the fiscal years ended May 31, 2005 and 2006 and for the quarters ended August 31, November 30, and February 28, during fiscal years 2006 and 2007 could no longer be relied upon.□

~~In this regard,~~If ~~during~~an ~~the~~emerging growth ~~preparation~~company, ofindicate ~~its~~by ~~May~~check ~~31,~~mark ~~2007~~if ~~consolidated financial statements,~~ the ~~Company~~registrant ~~concluded~~has ~~that~~elected itnot ~~was necessary~~ to ~~restate~~use ~~its financial results for~~ the ~~fiscal~~extended ~~years~~transition ~~ended~~period ~~May 31, 2006 and 2005 and~~ for ~~the~~complying ~~interim~~with ~~periods~~any ~~ended~~new ~~August~~or ~~31,~~revised ~~November~~financial ~~30,~~accounting ~~and~~standards ~~February~~provided ~~28,~~pursuant ~~during fiscal 2007 and 2006~~ to ~~reflect~~Section ~~additional~~13(a) ~~non-operating gains and losses related to the classification~~ of ~~and accounting for convertible notes issued in fiscal 2006 and 2005. The Company had previously recorded a beneficial conversion feature, valued~~ the ~~conversion~~Exchange ~~features and detachable warrants at the intrinsic value and classified the convertible instruments as equity~~Act. □

~~After further~~ITEM ~~review, the Company has determined that these instruments should have been classified as derivative liabilities pursuant to SFAS No~~5.02 ~~133~~Departure ~~and EITF No. 00-19. The accounting treatment~~ of ~~derivative financial instruments~~Directors ~~requires~~or ~~that~~Principal ~~the~~Officers; ~~Company~~Election ~~record the derivatives and related warrants at their fair values as~~ of ~~the~~Directors; ~~inception~~Appointment ~~date~~ of ~~and~~Principal atOfficers; ~~fair~~Compensatory ~~value~~Arrangements as of ~~each~~Certain ~~subsequent balance sheet date~~Officers. ~~At the date of the conversion of each respective instrument or portion thereof, the corresponding derivative liability will be reclassified as equity.~~

InEffective ~~particular~~February 20, ~~financial~~2020, ~~statements for~~ the ~~fiscal~~Board ~~years~~of ~~ended~~Directors ~~May~~(the ~~31,~~“Board”) ~~2005~~of ~~and 2006~~Avvaa ~~and~~World ~~for~~Health ~~the~~Care ~~quarters ended August 31~~Products, ~~November 30~~Inc., ~~and~~a ~~February~~Nevada ~~28, during~~corporation ~~fiscal~~(the ~~years~~“Company”) ~~2006~~appointed ~~and~~Dr.Stephanie ~~2007~~Willet ~~will~~as bea ~~restated~~member toof ~~reflect~~ the ~~additional non-operating~~Board ~~gains~~of Directors and ~~losses~~also ~~related~~naming ~~additional~~Ms. ~~penalties~~Willet ~~relating to~~as ~~convertible~~the ~~notes~~Company’s ~~outstanding~~interim-President, interim-Treasurer and interim-Secretary.

The sole executive officer of the company discussed with the Company’s independent auditors the matters disclosed in this Item 4.02 of the Form 8-K.

Item 9.01 Financial Statement And Exhibits.

(a) Financial Statements of Business Acquired.

None.

(b) Pro Forma Financial Information.

None

None.

SIGNATURES

~~Pursuant to~~In accordance with the requirements of the ~~Securities~~ Exchange Act ~~of 1934~~, the ~~Registrant has duly~~registrant caused this ~~Report~~report to be signed on its behalf by the undersigned, hereunto duly authorized.

	AVVAA WORLD HEALTH CARE PRODUCTS, INC.
Dated: November 1, 2007	By:	/s/ John Farley
DATED: March 11, 2020	By:	Stephanie Willet
		JOHN FARLEY Chief Executive Officer
		Stephanie Willet
		Interim-President (Principal Executive Officer)

Filing Compare · AVVAA WORLD HEALTH CARE PRODUCTS INC